U2Bio Co., Ltd. (KOSDAQ:221800)
South Korea
· Delayed Price · Currency is KRW 22,900
+1,000 (4.57%)
At close: Mar 9, 2026
U2Bio Revenue
U2Bio had revenue of 6.87B KRW in the quarter ending September 30, 2025, with 6.81% growth. This brings the company's revenue in the last twelve months to 25.59B, down -2.62% year-over-year. In the year 2024, U2Bio had annual revenue of 25.04B, down -18.68%.
Revenue (ttm)
25.59B
Revenue Growth
-2.62%
P/S Ratio
14.26
Revenue / Employee
n/a
Employees
n/a
Market Cap
364.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.04B | -5.75B | -18.68% |
| Dec 31, 2023 | 30.79B | -38.22B | -55.38% |
| Dec 31, 2022 | 69.01B | 58.01B | 527.29% |
| Dec 31, 2014 | 11.00B | 1.59B | 16.90% |
| Dec 31, 2013 | 9.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| YG-1 Co., Ltd. | 605.75B |
| KOLMAR BNH | 594.71B |
| Sang-A Frontec | 175.95B |
| Value Added Technology | 413.76B |
| Galaxia Moneytree | 127.06B |
| InBody Co.,Ltd | 226.62B |
| SBB Tech | 6.60B |
| OKins Electronics | 87.18B |